Updated: Jan 2, 2022
Bernard Bihari, MD, discoverer of the major clinical effects of low dose naltrexone, and David Gluck, MD, founding editor of the LDN website.
Key Info
- LDN Editor’s Blog
- The Latest News Concerning LDN
- Clinical Trials for LDN
- Further Questions and Answers about LDN
- What Others Are Saying About LDN
- Reliability Problem With Compounding Pharmacies
Disease-specific Pages
- Autoimmune Diseases
- Cancers
- HIV/AIDS
In-depth historical reports on LDN for HIV/AIDS:- "Low Dose Naltrexone in the Treatment of Acquired Immune Deficiency Syndrome," a paper presented in 1988 to the International AIDS Conference in Stockholm, Sweden, describing in detail the 1986 LDN HIV/AIDS clinical study.
- "Low Dose Naltrexone in the Treatment of HIV Infection," an informal description of the results in Dr. Bernard Bihari's private practice through September, 1996.
Early LDN Conferences (2005-2008)
- First Annual LDN Conference (2005): Report & Multimedia
- Second Annual LDN Conference (2006): Report & Multimedia
- Third Annual LDN Conference (2007): Report & Multimedia
- National Cancer Institute Conference (2007): Summary Report
- Fourth Annual LDN Conference (2008): Report & Multimedia